Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2140036 | Leukemia Research | 2007 | 4 Pages |
Abstract
We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D3 (VD3) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400 mg/day). The results suggested that TPA combined with imatinib (400 mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Baijun Fang, Yongping Song, Zhengtao Han, Xudong Wei, Quande Lin, Xiaoxiu Zhu, Ruyu Yang, Junzhong Sun, Guofeng Tian, Xinjian Liu, Guoshun Cao, Yin Shi, Neng Nie, Dapeng Li, Robert Chunhua Zhao,